Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Sep;28(6):263-73.
doi: 10.1002/bdd.551.

Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats

Anasuya Hazra  1 , Nancy Pyszczynski, Debra C DuBois, Richard R Almon, William J Jusko
Affiliations
Comparative Study

Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats

Anasuya Hazra et al. Biopharm Drug Dispos. 2007 Sep.

Abstract

Methylprednisolone (MPL) pharmacokinetics was examined in adrenalectomized (ADX) and normal rats to assess the feasibility of intramuscular (i.m.) dosing for use in pharmacodynamic studies. Several study phases were pursued. Parallel group studies were performed in normal and ADX rats given 50 mg/kg MPL (i.v. or i.m.) and blood samples were collected up to 6 h. Data from studies where normal rats were dosed with 50 mg/kg MPL i.m. and killed over either 6 or 96 h were combined to determine muscle site and plasma MPL concentrations. Lastly, ADX rats were dosed with 50 mg/kg MPL i.m. and killed over 18 h to assess hepatic tyrosine aminotransferase (TAT) dynamics. MPL exhibited bi-exponential kinetics after i.v. dosing with a terminal slope of 2.1 h(-1). The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability. The kinetics of MPL at the injection site exhibited slow, dual absorption rates. Although i.m. MPL showed lower bioavailability compared with other corticosteroids in rats, TAT dynamics revealed similar i.m. and i.v. response profiles. The more convenient intramuscular dosing can replace the i.v. route without causing marked differences in pharmacodynamics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmacokinetic model for methylprednisolone; the symbols are described in the text and Table 3
Figure 2
Figure 2
Pharmacokinetic profiles of methylprednisolone (50 mg/kg) after i.v. (top panel) and i.m. (bottom panel) administration in ADX and normal rats. Symbols depict mean observed data (four rats) ± SD
Figure 3
Figure 3
Pharmacokinetic profiles of MPL after i.v. (top panel) and i.m. (bottom panel) administration. Symbols depict the observed data, solid lines represent the mean predictions, and the dashed lines reflect the 95% CI of the predictions
Figure 4
Figure 4
Pharmacokinetic profile of MPL in the injection site after 50 mg/kg dosing of MPL in normal rats. Symbols depict individual observed data from rats, solid line represents the mean predictions, and the dashed lines reflect the 95% CI of the predictions
Figure 5
Figure 5
Simulated (based on model in Figure 1) pharmacokinetic profiles of MPL after i.v. (● Study 1-normal, Δ Study 1-ADX, □ data from Sun et al. [19]) and i.m. (Δ Study 1-normal, ▲ Study 1-ADX, ■ Study 2, ● Study 4) administration. Symbols depict the observed data ± SD, solid lines represent the mean prediction and the dashed lines reflect the 95% CI of 51 the predictions
Figure 6
Figure 6
Pharmacodynamics of tyrosine aminotransferase mRNA (top panel) and activity (bottom panel) in ADX rats after i.v. or i.m. administration of 50 mg/kg MPL. Symbols depict the observed data ± SD
See this image and copyright information in PMC

References

    1. Belvisi MG, Brown TJ, Wicks S, Foster ML. New glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther. 2001;14:221–227. - PubMed
    1. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23–43. - PubMed
    1. Boudinot FD, D’Ambrosio R, Jusko WJ. Receptor- mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986;14:469–493. - PubMed
    1. Haughey DB, Jusko WJ. Receptor-mediated methylprednisolone pharmacodynamics in rats: steroid-induced receptor down-regulation. J Pharmacokinet Biopharm. 1992;20:333–355. - PubMed
    1. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn. 2002;29:1–24. - PMC - PubMed

Publication types

MeSH terms